Tirzepatide
Pre-Order10 mg · Lyophilized powder
Available for pre-order
Dual GIP / GLP-1 receptor agonist peptide (LY3298176).
Need larger quantities? Wholesale pricing for qualified businesses
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. For laboratory research use only. Not for human or animal consumption.
Pre-Order Information
This product is currently available for pre-order. No payment is collected today. Estimated availability is approximately 2–4 weeks. We'll contact you when your reservation is ready for payment.
- 1Reserve todayNo payment now
- 2We prepare itAbout 2–4 weeks
- 3Payment requestBy email, with a secure link
- 4ShipsTracking by email
Quick Summary
FDA-approved ingredient (Mounjaro 2022, Zepbound 2023)Tirzepatide is a 39-amino-acid peptide from Eli Lilly that activates two gut-hormone receptors, GIP and GLP-1, which help regulate insulin release, blood sugar and appetite. It is the active ingredient of two FDA-approved prescription medicines, Mounjaro (type 2 diabetes) and Zepbound (chronic weight management and obstructive sleep apnea). This research-grade material is neither of those approved drug products.
Areas of research
- Type 2 diabetes
- Obesity
- Obstructive sleep apnea with obesity
- Receptor pharmacology
- Amount
- 10 mg
- Form
- Lyophilized powder
- References
- 5 cited
- COA
- Batch report pending
- Free U.S. shipping over $150
- Lyophilized powder in a sealed vial
Research Use Notice. This product is intended for laboratory and research purposes. It is not intended for human consumption or personal medical use. Product information is provided for scientific and educational context only. See our Research Use Policy.
Why Researchers Study It
- Combining GIP and GLP-1 receptor activity in one molecule
- Blood-sugar control in type 2 diabetes (SURPASS trial program)
- Body-weight regulation in obesity (SURMOUNT trial program)
- How GIP receptor activity adds to GLP-1 effects, studied in cells, animals and people
- Long-acting peptide design through fatty-acid attachment and albumin binding
What It IsTirzepatide (development code LY3298176) is a synthetic peptide of 39 amino acids with a C20 fatty diacid attached.
Tirzepatide (development code LY3298176) is a synthetic peptide of 39 amino acids with a C20 fatty diacid attached. The fatty chain binds blood albumin, which gives it a half-life of about five days.
A single molecule activates both the GIP receptor and the GLP-1 receptor, the two main incretin (gut-hormone) receptors that help regulate insulin release after meals. It was designed by Eli Lilly starting from the GIP hormone sequence.
The molecule, the approved medicines and this product are three different things. Tirzepatide is the molecule. Mounjaro (approved May 2022 for type 2 diabetes) and Zepbound (approved November 2023 for chronic weight management, and December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity) are Lilly's FDA-approved drug products, made and tested under FDA oversight. Renuvia's tirzepatide is research-grade material for laboratory use; it is not Mounjaro or Zepbound and has not been reviewed or approved by the FDA.
The FDA has warned about unapproved tirzepatide sold online, including products labeled "research use only", and has issued warning letters to sellers of such products.
How It Works3 established · 2 proposed or under investigation
Established
- Binds and activates both the GIP and GLP-1 receptors (FDA label); in cell assays it acts more strongly at the GIP receptor than at the GLP-1 receptor (Coskun 2018)
- Increases glucose-dependent insulin release and lowers glucagon levels (FDA label)
- Half-life of about five days, due to the attached C20 fatty diacid and albumin binding (FDA label)
Proposed / under investigation
- How much GIP receptor activity contributes to weight loss beyond GLP-1 activity is still debated
- Effects on appetite and food intake are thought to act through brain GLP-1 and GIP receptors; the pathways are not fully mapped in humans
Research Status & EvidenceFDA-approved ingredient (Mounjaro 2022, Zepbound 2023)
The approvals apply only to Lilly's Mounjaro and Zepbound. This product is research-grade material, not an approved drug, and has not been evaluated by the FDA.
Types of evidence
- Available: Cell & lab studies
- Available: Animal studies
- Not available: Early human studies
- Available: Clinical trials
- Available: Approved medical use
Tirzepatide has extensive clinical evidence, including large peer-reviewed phase 3 trials and full FDA approvals. In SURMOUNT-1, adults with obesity lost substantially more body weight over 72 weeks than with placebo. That evidence applies to the approved medicines made under FDA oversight, not to research-grade material of unverified identity, purity or sterility.
Areas of research
- Type 2 diabetesapproved indication (Mounjaro), SURPASS trials
- Obesityapproved indication (Zepbound), SURMOUNT trials
- Obstructive sleep apnea with obesityapproved indication (Zepbound, 2024)
- Receptor pharmacologydual GIP / GLP-1 agonism in cell assays and animals
Limitations
- FDA approval covers only Lilly's Mounjaro and Zepbound; this research-grade product is not an approved drug and has not been evaluated by the FDA
- The FDA has warned that unapproved GLP-1 products sold online, including ones labeled "research use only", are of unknown quality and may be harmful
- The approved labels carry a boxed warning for thyroid C-cell tumors, seen in rats; whether this applies to humans is unknown
- Most common side effects in trials were gastrointestinal (nausea, diarrhea, vomiting, constipation)
Specifications10 mg · Lyophilized powder · CAS 2023788-19-2
- Product
- Tirzepatide
- Category
- Peptides
- Size
- 10 mg
- Form
- Lyophilized powder
- Synonyms
- LY3298176; Tirz
- CAS number
- 2023788-19-2
- Molecular formula
- C225H348N48O68
- Molecular weight
- 4813.5 g/mol
- PubChem CID
- 156588324
- SKU
- REN-TIRZ-10
Molecular data: Free peptide (PubChem; formula and molecular weight also on the FDA label).
Testing & COA Batch report pending
Research References (5)Linked sources · last reviewed September 2026
- FDA. MOUNJARO (tirzepatide) prescribing information, Eli Lilly, revised January 2026 · accessdata.fda.gov
- FDA. FDA's concerns with unapproved GLP-1 drugs used for weight loss (updated September 2026) · fda.gov
- FDA. Warning letter to Summit Research Peptides (tirzepatide and other GLP-1 products sold as research use only), December 10, 2024 · fda.gov
- Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab 2018 · PubMed 30473097
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022 · PubMed 35658024
Summaries are written by Renuvia Labs from the sources above for educational context only. Last reviewed September 30, 2026.
Frequently Asked Questions
What form is this product supplied in?
Peptides and research compounds ship as lyophilized (freeze-dried) powder in a sealed glass vial. The fill amount printed on the product page and label is the total content of the vial.
Is this product for human use?
No. All Renuvia Labs products are sold strictly for laboratory research use. They are not for human or animal consumption and are not intended to diagnose, treat, cure or prevent any disease.
Where can I find the Certificate of Analysis?
When a batch has a Certificate of Analysis, it is linked in the Testing & COA section of the product page and listed in the COA library, searchable by product, SKU or batch number.
Do you offer volume pricing?
Yes. Per-vial pricing drops automatically at 2, 3 and 5 vials of the same product; the current tiers are shown next to the price. For larger quantities, see our wholesale program.
How much is shipping?
U.S. orders of $150 or more ship free. Orders below that ship at a flat rate, shown in the cart.
